Exercise to Slow Cardiovascular Ageing Progression

Exercise Clinical Trial

Official title:

Exercise to Slow Cardiovascular Ageing Progression

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05775484
• Other study ID #: 2022/2667
• Status: Recruiting
• Start date: May 1, 2023
• Est. completion date: December 31, 2051

Study information

• Verified date: May 2023
• Source: National Heart Centre Singapore
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In ageing, deleterious alterations in cardiovascular (CV) structure and function increase risks of ageing-related cardiovascular disease (CVD). Investigators found that these CV alterations were associated with circulating serum metabolites, suggesting a metabolic basis to CV ageing. Investigators hypothesize that modification of these metabolites by intervention, such as exercise, may retard CV alterations and reduce CVD in ageing.

Description:

Participants from each stratum will be randomized to receive either an exercise program intervention or no exercise. At the start and end of study, participants will undergo cardiovascular imaging and metabolic profiling. Investigators will determine if exercise can reverse high-risk metabolic profiles and improve cardiovascular structure and function.

Without clear mechanisms to explain cardiovascular ageing nor interventions known to retard cardiovascular ageing, our approach will provide much needed translational evidence to incorporate targeted interventions aimed at reducing cardiovascular disease risk in older populations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 450
• Est. completion date: December 31, 2051
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 100 Years

Eligibility

Inclusion Criteria:

• Age >=21 years old

• Outdoor ambulant

Exclusion Criteria:

• Wheelchair or bed-bound

• Dementia

• Residing in sheltered or nursing home

• Cancer

• Participation in ongoing clinical trials that involve interventional drugs or devices

• Aneurysms

• Acute infections (in the last six months)

• Uncontrolled thyrotoxicosis

• Neuromuscular, musculoskeletal or rheumatoid disorders that are exacerbated by exercise

• Uncontrolled asthma or chronic lung disease

• Restrictive lung disease

Related Conditions & MeSH terms

• Cardiac Ageing
• Cardiovascular
• Exercise

Locations

Country	Name	City	State
Singapore	National Heart Centre Singapore	Singapore

Sponsors (1)

Lead Sponsor	Collaborator
National Heart Centre Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Metabolite profiles	To measure changes in serum metabolite levels among participants pre and post exercise intervention.	12 Months
Primary	Cardiovascular structure and function	To measure changes in CV structure and function (diastolic function, arterial stiffness) among participants.	12 Months